Aclaris Therapeutics (ACRS) Competitors $1.67 -0.03 (-1.76%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$1.67 0.00 (0.00%) As of 03/25/2025 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS vs. MRVI, DNTH, LENZ, CRMD, SION, ORGO, ABUS, SANA, CDXC, and KALVShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Maravai LifeSciences (MRVI), Dianthus Therapeutics (DNTH), LENZ Therapeutics (LENZ), CorMedix (CRMD), Sionna Therapeutics (SION), Organogenesis (ORGO), Arbutus Biopharma (ABUS), Sana Biotechnology (SANA), ChromaDex (CDXC), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. Maravai LifeSciences Dianthus Therapeutics LENZ Therapeutics CorMedix Sionna Therapeutics Organogenesis Arbutus Biopharma Sana Biotechnology ChromaDex KalVista Pharmaceuticals Aclaris Therapeutics (NASDAQ:ACRS) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation. Which has more volatility & risk, ACRS or MRVI? Aclaris Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500. Does the MarketBeat Community believe in ACRS or MRVI? Aclaris Therapeutics received 325 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. Likewise, 66.67% of users gave Aclaris Therapeutics an outperform vote while only 60.58% of users gave Maravai LifeSciences an outperform vote. CompanyUnderperformOutperformAclaris TherapeuticsOutperform Votes38866.67% Underperform Votes19433.33% Maravai LifeSciencesOutperform Votes6360.58% Underperform Votes4139.42% Does the media prefer ACRS or MRVI? In the previous week, Maravai LifeSciences had 46 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 56 mentions for Maravai LifeSciences and 10 mentions for Aclaris Therapeutics. Maravai LifeSciences' average media sentiment score of 0.09 beat Aclaris Therapeutics' score of -0.12 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 6 Very Positive mention(s) 8 Positive mention(s) 32 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Is ACRS or MRVI more profitable? Maravai LifeSciences has a net margin of -81.13% compared to Aclaris Therapeutics' net margin of -136.65%. Maravai LifeSciences' return on equity of -6.61% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-136.65% -40.26% -31.71% Maravai LifeSciences -81.13%-6.61%-3.45% Do insiders & institutionals have more ownership in ACRS or MRVI? 98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 6.4% of Aclaris Therapeutics shares are held by insiders. Comparatively, 0.6% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend ACRS or MRVI? Aclaris Therapeutics currently has a consensus target price of $11.67, indicating a potential upside of 598.60%. Maravai LifeSciences has a consensus target price of $7.59, indicating a potential upside of 230.16%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than Maravai LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has preferable valuation & earnings, ACRS or MRVI? Aclaris Therapeutics has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$18.72M9.63-$88.48M-$1.51-1.11Maravai LifeSciences$259.19M2.24-$119.03M-$1.02-2.25 SummaryAclaris Therapeutics beats Maravai LifeSciences on 11 of the 19 factors compared between the two stocks. Remove Ads Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$180.23M$6.99B$5.68B$8.32BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-3.217.2324.5519.25Price / Sales9.63230.77395.7294.09Price / CashN/A65.6738.1634.64Price / Book0.756.617.064.46Net Income-$88.48M$142.13M$3.19B$247.07M7 Day Performance5.70%2.79%1.49%3.05%1 Month Performance-18.93%2.70%5.87%-2.85%1 Year Performance43.97%-4.42%14.94%4.63% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics2.7936 of 5 stars$1.67-1.8%$11.67+598.6%+44.0%$180.23M$18.72M-3.21100MRVIMaravai LifeSciences4.7562 of 5 stars$2.64+7.8%$9.28+251.6%-72.9%$666.67M$276.92M-1.61610Analyst ForecastGap UpDNTHDianthus Therapeutics1.3268 of 5 stars$21.97+3.0%$52.14+137.3%-41.0%$650.25M$6.24M-8.7980High Trading VolumeLENZLENZ Therapeutics2.1712 of 5 stars$23.59-7.3%$35.40+50.1%+61.9%$648.75MN/A0.00110Earnings ReportAnalyst RevisionCRMDCorMedix2.0388 of 5 stars$10.47flat$16.00+52.8%+79.9%$635.29M$12.26M-12.9330Earnings ReportAnalyst ForecastOptions VolumeNews CoverageGap DownSIONSionna TherapeuticsN/A$14.89-0.6%$38.50+158.6%N/A$633.14MN/A0.0035Earnings ReportORGOOrganogenesis3.1113 of 5 stars$4.97-0.8%$5.50+10.7%+99.2%$630.34M$482.04M-82.83950ABUSArbutus Biopharma2.2125 of 5 stars$3.28-0.6%$5.50+67.7%+35.3%$621.53M$6.74M-7.6390Upcoming EarningsSANASana Biotechnology3.1032 of 5 stars$2.77-5.5%$12.25+342.2%-76.3%$618.46MN/A-1.98380News CoverageCDXCChromaDex4.3939 of 5 stars$7.94+1.3%$9.03+13.8%N/A$617.34M$99.60M794.79120KALVKalVista Pharmaceuticals4.4803 of 5 stars$12.49-0.9%$23.80+90.6%+12.3%$617.23MN/A-3.43100 Remove Ads Related Companies and Tools Related Companies Maravai LifeSciences Competitors Dianthus Therapeutics Competitors LENZ Therapeutics Competitors CorMedix Competitors Sionna Therapeutics Competitors Organogenesis Competitors Arbutus Biopharma Competitors Sana Biotechnology Competitors ChromaDex Competitors KalVista Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRS) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACRS Stock Free ACRS Stock Alerts